Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis

American Journal of Hematology

Volumn 81, Issue 6, 2006, Pages 420-422

  Ikhlaque, Nadeem ^a   Seshadri, Vidya ^a   Kathula, Satheesh ^a   Baumann, Michael A ^a,b,c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Medicine (111W)   (United States)

Author keywords

Anticoagulation; Deep venous thrombosis; Thalidomide; Warfarin

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; TEMOZOLOMIDE; THALIDOMIDE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASIA; MYELOFIBROSIS; MYELOMA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK REDUCTION; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; THALIDOMIDE; VENOUS THROMBOSIS; WARFARIN;

EID: 33646883735     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20625     Document Type: Review

References (8)

1. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003;21:4444-4454.
2. Kumar S, Witzing TE, Rajkumar SV. Thalidomide: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 2004;22:2477-2488.
3. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-19.
4. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715-721.
5. Minnema MC, Breitkreutz I, Auwerda JJA, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004;18:2044-2046 (letter).
6. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med 2004;351:1860-1873.
7. Lee AYY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
8. Klerk CPW, Smorenburg SM, Hans-Martin O, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.